- Home
- CRESY vs CVAC Comparison
CRESY vs CVAC Comparison
Compare CRESY & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRESY
- CVAC
- Stock Information
- Founded
- CRESY 1936
- CVAC 2000
- Country
- CRESY Argentina
- CVAC Germany
- Employees
- CRESY N/A
- CVAC N/A
- Industry
- CRESY Real Estate
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CRESY Finance
- CVAC Health Care
- Exchange
- CRESY Nasdaq
- CVAC Nasdaq
- Market Cap
- CRESY 716.0M
- CVAC 818.8M
- IPO Year
- CRESY 1997
- CVAC 2020
- Fundamental
- Price
- CRESY $11.72
- CVAC $3.17
- Analyst Decision
- CRESY
- CVAC Buy
- Analyst Count
- CRESY 0
- CVAC 2
- Target Price
- CRESY N/A
- CVAC $10.00
- AVG Volume (30 Days)
- CRESY 262.2K
- CVAC 690.2K
- Earning Date
- CRESY 05-09-2025
- CVAC 04-10-2025
- Dividend Yield
- CRESY 12.91%
- CVAC N/A
- EPS Growth
- CRESY N/A
- CVAC N/A
- EPS
- CRESY N/A
- CVAC 0.75
- Revenue
- CRESY $693,188,092.00
- CVAC $554,073,921.00
- Revenue This Year
- CRESY N/A
- CVAC N/A
- Revenue Next Year
- CRESY N/A
- CVAC $66.34
- P/E Ratio
- CRESY N/A
- CVAC $4.29
- Revenue Growth
- CRESY N/A
- CVAC 895.54
- 52 Week Low
- CRESY $6.56
- CVAC $2.22
- 52 Week High
- CRESY $14.23
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- CRESY 54.75
- CVAC 54.64
- Support Level
- CRESY $11.46
- CVAC $3.06
- Resistance Level
- CRESY $12.46
- CVAC $3.02
- Average True Range (ATR)
- CRESY 0.80
- CVAC 0.19
- MACD
- CRESY 0.15
- CVAC 0.05
- Stochastic Oscillator
- CRESY 77.30
- CVAC 82.25
About CRESY Cresud S.A.C.I.F. y A.
Cresud SACIF y A is engaged in agricultural business and urban properties and investment business. Under its agricultural business the company produces oilseed grains and cereals, sugar cane and meat. The Agricultural business of the company is further comprised of four reportable segments which are Agricultural production, Land transformation and Sales, Corporate and Other segments. The company participates in the real estate business in Argentina through its subsidiary IRSA. The real estate business is further comprised of five reportable segments, namely Shopping Malls, Offices, Sales and Developments, Hotels and others.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.